Wie ist das Verhältnis von IART zu PS im Vergleich zu anderen Unternehmen?

IART ist auf der Grundlage des Verhältnisses Price-To-Sales (1.2x) im Vergleich zum Durchschnitt der Vergleichsgruppe (2.5x) ein guter Wert.

Wie ist das Verhältnis von IART zu PS im Vergleich zu anderen Unternehmen der Branche US Medical Equipment?

IART ist aufgrund des Verhältnisses Price-To-Sales (1.2x) im Vergleich zum Branchendurchschnitt US Medical Equipment (3.3x) ein guter Wert.

Wie hoch ist das PS Verhältnis von IART im Vergleich zu seinem fairen PS Verhältnis? Dies ist das erwartete PS Verhältnis unter Berücksichtigung des prognostizierten Gewinnwachstums des Unternehmens, der Gewinnspannen und anderer Risikofaktoren.

IART ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Sales (1.2x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Sales (2.1x).

Wie hoch ist der faire Preis von IART, wenn man die zukünftigen Cashflows betrachtet? Für diese Schätzung verwenden wir ein Discounted-Cashflow-Modell.

IART ($23.7) wird unter unserer Schätzung des [[Fair Value]] ($57.94) gehandelt.

Wie sieht die 12-Monats-Prognose der Analysten aus und haben wir statistisches Vertrauen in das Konsenskursziel?

Das Kursziel liegt weniger als 20% über dem aktuellen Aktienkurs.

Integra LifeSciences Holdings (Nasdaq:IART) - Aktienkurs, Nachrichten und Analyse

IART Aktienübersicht

IART grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	5/6
Künftiges Wachstum	3/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	2/6
Dividenden	0/6

Belohnungen

59.1% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 113.69% pro Jahr

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Die Verschuldung ist durch den operativer Cashflow nicht gut gedeckt

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

LifeSciences' Operational Excellence And Tactical Growth To Propel Revenue And Earnings Forward

Key Takeaways The company's focus on quality management and compliance could enhance efficiencies and boost net margins, while infrastructure improvements aim to strengthen production capabilities. Leadership changes and strong performance in key segments are expected to drive strategic growth, potentially boosting revenue and earnings positively.

View narrative

US$28.11

15.7% undervalued

6.74%

Revenue growth p.a.

7 days ago

Integra LifeSciences Holdings Corporation Wettbewerber

NovoCure

NasdaqGS:NVCR

US$2.0b

Omnicell

NasdaqGS:OMCL

US$2.1b

Tandem Diabetes Care

NasdaqGM:TNDM

US$2.0b

NuVasive

NasdaqGS:NUVA

US$2.1b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Integra LifeSciences Holdings
Historische Aktienkurse
Aktueller Aktienkurs	US$23.70
52-Wochen-Hoch	US$45.42
52-Wochen-Tief	US$16.81
Beta	1.08
11 Monat Veränderung	25.07%
3 Monate Veränderung	16.46%
1 Jahr Veränderung	-39.32%
33 Jahre Veränderung	-62.94%
5 Jahre Veränderung	-60.82%
Veränderung seit IPO	412.43%

Aktuelle Nachrichten und Updates

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Nov 05

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Oct 24

Recent updates

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Nov 05

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Oct 24

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Sep 08

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Aug 21

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Jul 01

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Jun 21

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

May 28

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

Feb 27

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Feb 11

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jan 14

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Dec 31

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Dec 03

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Nov 06

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Oct 24

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Sep 22

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Aug 15

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Jul 03

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Jun 19

Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

May 05

These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well

Apr 07

Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital

Mar 26

At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?

Mar 14

Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?

Feb 27

Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Feb 02

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Jan 05

Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return

Dec 21

When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Dec 08

Aktionärsrenditen

	IART	US Medical Equipment	US Markt
7D	3.6%	1.2%	2.0%
1Y	-39.3%	22.6%	32.4%

Rendite im Vergleich zur Industrie: IART unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von 22.6% erzielte.

Rendite vs. Markt: IART hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 32.4 erzielte.

Preisvolatilität

Is IART's price volatile compared to industry and market?
IART volatility
IART Average Weekly Movement	9.0%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Stabiler Aktienkurs: IART hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: IARTDie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1989	3,946	Jan De Witte	www.integralife.com

Die Integra LifeSciences Holdings Corporation produziert und vertreibt chirurgische Instrumente, neurochirurgische Produkte und Wundversorgungsprodukte für den Einsatz in der Neurochirurgie, der neurokritischen Pflege und der Hals-Nasen-Ohrenheilkunde. Das Unternehmen ist in zwei Segmenten tätig: Codman Specialty Surgical und Tissue Technologies. Das Unternehmen bietet Produkte für die Neurochirurgie und die neurokritische Versorgung an, darunter Geräte für die Gewebeablation, Produkte für die Duralreparatur, Geräte für das Management der zerebralen Rückenmarksflüssigkeit, Geräte für die intrakranielle Überwachung und Geräte für die kraniale Stabilisierung sowie chirurgische Scheinwerfer und Instrumente sowie Dienstleistungen für den Anschlussmarkt.

Integra LifeSciences Holdings Corporation's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Integra LifeSciences Holdings im Vergleich zum Marktanteil des Unternehmens?
IART grundlegende Statistiken
Marktanteil	US$1.87b
Gewinn(TTM)	-US$6.54m
Umsatz(TTM)	US$1.56b

1.2x

Kurs-Umsatz-Verhältnis

-279.4x

Kurs-Gewinn-Verhältnis

Ist IART zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
IART Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$1.56b
Kosten der Einnahmen	US$632.40m
Bruttogewinn	US$932.52m
Sonstige Ausgaben	US$939.06m
Umsatz	-US$6.54m

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.085
Bruttomarge	59.59%
Nettogewinnspanne	-0.42%
Schulden/Eigenkapital-Verhältnis	118.9%

Wie hat sich IART auf lange Sicht entwickelt?

Historische Performance und Vergleiche

IART Aktienübersicht

Belohnungen

Risikoanalyse

LifeSciences' Operational Excellence And Tactical Growth To Propel Revenue And Earnings Forward

Integra LifeSciences Holdings Corporation Wettbewerber

NasdaqGS:NVCR

US$2.0b

NasdaqGS:OMCL

US$2.1b

NasdaqGM:TNDM

US$2.0b

NasdaqGS:NUVA

US$2.1b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Integra LifeSciences Holdings Corporation Announces Chief Executive Officer Changes

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023)

Investor sentiment improves as stock rises 25%

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Recent updates

Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024

There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise

Integra LifeSciences Holdings Corporation Announces Chief Executive Officer Changes

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023)

Investor sentiment improves as stock rises 25%

Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S

Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?

Consensus EPS estimates fall by 89%

Price target decreased by 18% to US$28.20

Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Third Quarter and Updates Earnings Guidance for the Full Year of 2024

Investor sentiment deteriorates as stock falls 19%

Integra LifeSciences Holdings Corporation to Report Q2, 2024 Results on Jul 29, 2024

Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from Russell 1000 Dynamic Index

At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Still Underperforming As Manufacturing Issues Linger

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price

Independent Presiding Director recently bought US$996k worth of stock

Consensus EPS estimates fall by 19%, revenue upgraded

Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2024

Price target decreased by 21% to US$35.20

Full year 2023 earnings released: EPS: US$0.85 (vs US$2.18 in FY 2022)

Investor sentiment deteriorates as stock falls 21%

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Integra LifeSciences Holdings Corporation, Annual General Meeting, May 09, 2024

Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases

Insider notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 17%

Consensus EPS estimates fall by 31%

Integra LifeSciences Holdings Corporation Announces Board Changes

Full year 2023 earnings: EPS misses analyst expectations

Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled

We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt

Integra LifeSciences Holdings Corporation to Report Q4, 2023 Results on Feb 28, 2024

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?

Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Profit margin trend

Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns

Levi & Korsinsky Notifies Integra Lifesciences Holdings Corporation Investors of a Class Action Lawsuit and Upcoming Deadline

Integra LifeSciences Holdings Corporation to Report Q3, 2023 Results on Oct 25, 2023

Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation

Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?

Consensus EPS estimates fall by 17%

New minor risk - Earnings quality

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) announces an Equity Buyback for $225 million worth of its shares.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Integra LifeSciences Holdings Corporation to Report Q2, 2023 Results on Jul 27, 2023

Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes

Integra LifeSciences Holding Corporation Announces Complete Enrollment in DuraSorb Monofilament Mesh U.S. IDE Study

Integra Lifesciences Holdings Corporation Appoints Lea Daniels Knight as Executive Vice President, Effective June 28, 2023

Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?

Erträge & Einnahmen